A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
Stopped early · Phase 1/Phase 2
Conditions studied: Solid Tumors
In brief
The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with advanced or metastatic malignancies.
Key facts
- Study ID
- NCT03347123
- Run by
- Incyte Corporation
- People needed
- 11
- Starts
- 2018-03-21
- Expected to finish
- 2021-01-29
- Last updated by the study team
- 2022-02-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- During Phase 1, participant with locally advanced or metastatic solid tumors with disease progression on or after treatment with available therapies, or who are intolerant to treatment, or who refuse standard treatment.
- During Phase 2, participant with advanced cancer who have received at least one prior therapy or are treatment naive, depending on the specified tumor type.
- Presence of measurable disease per RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Expected survival of ≥ 12 weeks.
You may not qualify if…
- Laboratory and medical history parameters not within the Protocol-defined range.
- Receipt of anticancer medications or investigational drugs within Protocol-defined time frames.
- Previous radiotherapy within 7 days of Cycle 1 Day 1.
- Known active central nervous system metastases and/or carcinomatous meningitis.
- Prior treatment with any immune checkpoint inhibitor and/or an IDO inhibitor.
- Active infection requiring systemic therapy.
- Any active or inactive autoimmune disease or syndrome
Where it is running
- University of Alabama at Birmingham — Birmingham, Alabama, United States
- The Angeles Clinic and Research Institute — Los Angeles, California, United States
- John Wayne Cancer Institute — Santa Monica, California, United States
- Duke University Medical Center — Durham, North Carolina, United States
- Vanderbilt University Medical Center — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.